Immunic Analyst Ratings
EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Immunic Stock's Popularity Rises With Consistent Buy Ratings From Analysts
Brookline Capital Maintains Immunic(IMUX.US) With Buy Rating, Raises Target Price to $13
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Immunic, Inc. on Promising MS Drug Developments and Favorable Market Position
Immunic Initiated at Buy by EF Hutton
Immunic Analyst Ratings
EF Hutton Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $17
Leerink Partners Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $5
Piper Sandler Sticks to Their Buy Rating for Immunic (IMUX)
Immunic Price Target Announced at $6.00/Share by B. Riley Securities
Immunic Initiated at Buy by B. Riley Securities
Immunic Analyst Ratings
B. Riley Securities Initiates Immunic at Buy With $6 Price Target
B.Riley Financial Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $6
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aldeyra Therapeutics (ALDX) and Immunic (IMUX)
Piper Sandler Reiterates Overweight on Immunic, Maintains $28 Price Target